Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Lipocine Inc

LPCN ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.44

▼ -5.26%

Market Cap $11.87M · Vol 22.05K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$11.87M

Micro Cap

Div Yield

N/A

EPS Growth

+12.71%

YoY

RSI (14)

34.29

Momentum

Beta

0.45

vs Market

52W High

$12.35

88.34% below

52W Low

$1.41

2.13% above

Volume

22.05K

Avg 291.84K

P/B

3.42

Price-to-book

ROE

N/A

Return on equity

Free Float

95.04%

Public shares

Shariah Compliance8 STANDARDS

✗ Lipocine Inc (LPCN) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does LPCN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-34.55%

-31.75%

-38.20%

YTD

-82.07%

-44.62%

-43.53%

-91.86%

Financials & Valuation

TTM · Annual

Total Revenue	$1.98M
Net Income	$-9,627,510.00
Revenue Growth (YoY)	-69.48%
Gross Margin	100.00%
Operating Margin	-524.69%
Net Profit Margin	-487.06%
ROE	N/A
ROA · ROIC	-48.73% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	22.14
P/B	3.42
P/FCF	N/A
EPS Growth	+12.71%
Outstanding Shares	8.24M

Technical Indicators

50-Day SMA	$1.99
200-Day SMA	$3.91
RSI (14)	34.29
Beta	0.45
52-Week High	$12.35
52-Week Low	$1.41

Volume Today	22.05K
Avg Daily Volume (30D)	291.84K
Relative Volume	0.08x
Volatility (10D)	63.10
Volatility (30D)	70.61
Free Float	95.04%

Analyst Consensus

BUY

Current Price $1.44

Mean Target $5.00

52W Low$1.41 52W High$12.35

Current

Target

$1.41 $12.35

Current Analyst target

+247.22% upside potential · 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG0029L1Y76

ISINUS53630X2036

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -2.98% ARGX.BR argenx SE +0.35% ARGX argenx SE -0.55% GMAB.CO Genmab A/S +3.27% GMAB Genmab A/S +1.01%

Company Profile

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.